CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans and their members to prescription savings, announces today its GLP-1 ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS said Caremark will offer Wegovy at "a more affordable ... investors worried about direct competition in the market between Zepbound and Wegovy. Lilly executives remained unfazed about the ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...